Mario A. Eisenberger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mario A. Eisenberger has a total of 192 co-authors. Here are the top co-authors by number of shared publications:
- Emmanuel S. Antonarakis
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
128 shared publications - Mark Christopher Markowski
Sidney Kimmel Comprehensive Cancer Center 1 Baltimore, Maryland
124 shared publications - Channing Judith Paller
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
123 shared publications - Michael Anthony Carducci
Johns Hopkins School of Medicine Department of Oncology Baltimore, Maryland, 21287
123 shared publications - Samuel R. Denmeade
Sidney Kimmel Comprehensive Cancer Center 1 Baltimore, Maryland
121 shared publications - Catherine Handy Marshall
Sidney Kimmel Comprehensive Cancer Center 1 Baltimore, Maryland
119 shared publications
Latest Publications
- 19 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500688
Comparison of Characteristics and Outcomes of Patients With Metastatic Prostate Cancer With and Without Next-Generation Sequencing Testing
PURPOSE: Next-generation sequencing (NGS) is recommended for patients with metastatic prostate cancer (PC). Nationwide, testing rates are low. Whether PC disease characteristics and courses differ between those with and without NGS testing is unknown. We identified predictors of testing, explored likely reasons for lack of testing, and compared survival between those with and without testing. METHODS: We retrospectively reviewed patients with metastatic PC initially seen between 2020 and 2022 at Johns Hopkins. Clinical data and reasons for nontesting were abstracted from the electronic medical record. We conducted a logistic regression assessing predictors of NGS testing, adjusting for age, Gleason grade, marital status, and metastatic diagnosis year. We used Cox regression to compare overall survival, defined from the time patients had both a metastatic diagnosis and a visit at our institution until death/last follow-up, between those tested and not tested. We adjusted for age, Gleason grade, initial metastasis (M) stage, comorbidities, and time from metastatic diagnosis to first visit. RESULTS: Of the 435 patients, 257 (59%) had NGS testing. Older patients were less likely to have testing (adjusted odds ratio [aOR], 0.96 [95% CI, 0.94 to 0.98]). Unmarried patients were less likely to have testing (aOR, 0.62 [95% CI, 0.38 to 1.01]). Patients with Gleason Grade Group 5 were more likely to undergo testing than patients with Groups 1-3 (aOR, 1.86 [95% CI, 1.14 to 3.04]). Among those without testing, 139 (78%) had at least one potential reason for lack of testing in the medical record. The most common reason for nontesting was patient/disease factors (37%). CONCLUSION: Older and unmarried men with metastatic PC were less likely to obtain NGS testing, whereas those with high Gleason grade were more likely. Interventions are needed to improve testing rates.
- 19 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500688
Comparison of Characteristics and Outcomes of Patients With Metastatic Prostate Cancer With and Without Next-Generation Sequencing Testing
PURPOSE: Next-generation sequencing (NGS) is recommended for patients with metastatic prostate cancer (PC). Nationwide, testing rates are low. Whether PC disease characteristics and courses differ between those with and without NGS testing is unknown. We identified predictors of testing, explored likely reasons for lack of testing, and compared survival between those with and without testing. METHODS: We retrospectively reviewed patients with metastatic PC initially seen between 2020 and 2022 at Johns Hopkins. Clinical data and reasons for nontesting were abstracted from the electronic medical record. We conducted a logistic regression assessing predictors of NGS testing, adjusting for age, Gleason grade, marital status, and metastatic diagnosis year. We used Cox regression to compare overall survival, defined from the time patients had both a metastatic diagnosis and a visit at our institution until death/last follow-up, between those tested and not tested. We adjusted for age, Gleason grade, initial metastasis (M) stage, comorbidities, and time from metastatic diagnosis to first visit. RESULTS: Of the 435 patients, 257 (59%) had NGS testing. Older patients were less likely to have testing (adjusted odds ratio [aOR], 0.96 [95% CI, 0.94 to 0.98]). Unmarried patients were less likely to have testing (aOR, 0.62 [95% CI, 0.38 to 1.01]). Patients with Gleason Grade Group 5 were more likely to undergo testing than patients with Groups 1-3 (aOR, 1.86 [95% CI, 1.14 to 3.04]). Among those without testing, 139 (78%) had at least one potential reason for lack of testing in the medical record. The most common reason for nontesting was patient/disease factors (37%). CONCLUSION: Older and unmarried men with metastatic PC were less likely to obtain NGS testing, whereas those with high Gleason grade were more likely. Interventions are needed to improve testing rates.
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S10 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S10 shows ANCOVA Least-squares Means for Cycle 4, 6, and 8 FACT-P Total by Study Arm
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S10 shows ANCOVA Least-squares Means for Cycle 4, 6, and 8 FACT-P Total by Study Arm
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S3 shows Adverse Events Included in the Co-Primary Endpoint: All Occurrences
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S3 shows Adverse Events Included in the Co-Primary Endpoint: All Occurrences
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S1 shows Participating Sites and the Number of Patients Enrolled in the Trial at Each Institution
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S1 shows Participating Sites and the Number of Patients Enrolled in the Trial at Each Institution
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S9 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S9 shows FACT-P Total Scores: Baseline, Cycles 4, 6, and 8
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S9 shows FACT-P Total Scores: Baseline, Cycles 4, 6, and 8
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S6 shows AEs with Attribution Possible, Probable or Definite to Docetaxel listed by types and grades
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S6 shows AEs with Attribution Possible, Probable or Definite to Docetaxel listed by types and grades
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S5 shows AEs with Attribution Possible, Probable or Definite to Treatment (HDVIC or Placebo) listed by types and grades
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S5 shows AEs with Attribution Possible, Probable or Definite to Treatment (HDVIC or Placebo) listed by types and grades
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary: Trial Protocol from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Trial Protocol shows the details of the study
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary: Trial Protocol from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Trial Protocol shows the details of the study
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S15 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S15 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 6
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S15 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S15 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 6